☰

Jordan S. Fridman, Ph.D. - Publications

Affiliations: 
2000 University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Pharmacology, Cell Biology, Oncology
Tree Info Grants Similar researchers PubMed Report error

9 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Shin N, Li YL, Mei S, Wang KH, Hall L, Katiyar K, Wang Q, Yang G, Rumberger B, Leffet L, He X, Rupar M, Bowman K, Favata M, Li J, ... ... Fridman J, et al. INCB040093 is a novel PI3Kδinhibitor for the treatment of B cell lymphoid malignancies. The Journal of Pharmacology and Experimental Therapeutics. PMID 29127109 DOI: 10.1124/jpet.117.244947  0.311
2010 Liu X, Shin N, Koblish HK, Yang G, Wang Q, Wang K, Leffet L, Hansbury MJ, Thomas B, Rupar M, Waeltz P, Bowman KJ, Polam P, Sparks RB, Yue EW, ... ... Fridman JS, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 115: 3520-30. PMID 20197554 DOI: 10.1182/blood-2009-09-246124  0.32
2010 Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. Neoplasia (New York, N.Y.). 12: 28-38. PMID 20072651 DOI: 10.1593/neo.91192  0.3
2004 Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J, Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428: 332-7. PMID 15029198 DOI: 10.1038/Nature02369  0.338
2003 Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 22: 9030-40. PMID 14663481 DOI: 10.1038/sj.onc.1207116  0.33
2001 Fridman JS, Parsels J, Rehemtulla A, Maybaum J. Cytochrome c depletion upon expression of Bcl-XS. The Journal of Biological Chemistry. 276: 4205-10. PMID 11044452 DOI: 10.1074/Jbc.M008171200  0.621
1999 Rehemtulla A, Hamilton AC, Taneja N, Fridman J, Juan TS, Maybaum J, Chinnaiyan A. A caspase-resistant form of Bcl-X(L), but not wild type Bcl-X(L), promotes clonogenic survival after ionizing radiation. Neoplasia (New York, N.Y.). 1: 63-70. PMID 10935471 DOI: 10.1038/Sj.Neo.7900013  0.588
1999 Fridman JS, Benedict MA, Maybaum J. bcl-X(S)-induced cell death in 3T3 cells does not require or induce caspase activation. Cancer Research. 59: 5999-6004. PMID 10606248  0.655
1998 Fridman JS, Rehemtulla A, Hofmann A, Blau HM, Maybaum J. Expression of Bcl-XS alters cytokinetics and decreases clonogenic survival in K12 rat colon carcinoma cells. Oncogene. 17: 2981-91. PMID 9881700 DOI: 10.1038/Sj.Onc.1202224  0.61
Show low-probability matches.